MetaCap

Onconetix (ONCO) vs Traws Pharma (TRAW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Traws Pharma is the larger company by market cap ($2.7 million vs $2.4 million), about 1.1 times the size. Traws Pharma converts more of its revenue into profit, with a net margin of 328.7% versus -1721.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ONCO+383.92%TRAW-63.47%
+1120%+500%-120%
Oct 7, 20261 yearNov 20, 2026
ONCO+366.13%TRAW-60.69%
+1075%+480%-115%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ONCO versus TRAW key metrics
MetricONCOTRAW
Share price$2.89$0.175
Market cap$2.37M$2.69M
1-day change-8.54%-23.91%
P/E ratio (TTM)0.00—
EPS (TTM)$4,509.80$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$815.37K$2.79M
Revenue growth (YoY)-67.70%+1134.51%
Net income (latest FY)$-14.03M$9.17M
Gross margin77.62%—
Operating margin-2190.03%-640.68%
Net margin-1720.98%328.67%
52-week high$1,610.00$3.23
52-week low$2.76$0.1698
Distance from 52-week high-99.82%-94.58%
Analyst consensus—none
Avg. price target upside—+471.43%
Average volume412.90K610.04K
Shares outstanding820.61K15.37M
Employees24
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Traws Pharma is more profitable, keeping 328.7 cents of every revenue dollar as net income versus -1721.0 cents for Onconetix.
  • Traws Pharma grew revenue faster in its latest fiscal year (+1134.51% vs -67.70%).

About Onconetix

ONCO stock →

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About Traws Pharma

TRAW stock →

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

ONCO vs TRAW FAQ

Which is bigger, Onconetix or Traws Pharma?

Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.37M for Onconetix (ONCO).

Are Onconetix and Traws Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons